• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
  •   LillOA Home
  • Liste des unités
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Allogeneic hematopoietic cell transplantation ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1016/j.bulcan.2017.06.020
PMID :
29173978
Permalink :
http://hdl.handle.net/20.500.12210/4323
Title :
Allogeneic hematopoietic cell transplantation for Hodgkin''s disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Author(s) :
Gauthier, Jordan [Auteur]
Chantepie, Sylvain [Auteur]
Bouabdallah, Krimo [Auteur]
Jost, Edgar [Auteur]
Nguyen, Stephanie [Auteur]
Gac, Anne-Claire [Auteur]
Damaj, Gandhi [Auteur]
Dulery, Remy [Auteur]
Michallet, Mauricette [Auteur]
Delage, Jeremy [Auteur]
Lewalle, Philippe [Auteur]
Morschhauser, Franck [Auteur] refId
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Salles, Gilles [Auteur]
Yakoub-Agha, Ibrahim [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Cornillon, Jerome [Auteur]
Journal title :
Bulletin du cancer
Abbreviated title :
Bull. Cancer
Volume number :
104
Pages :
S112-S120
Publication date :
2017
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially ...
Show more >
Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allogeneic haematopoietic cell transplantation for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This manuscript specifically reports on our conclusions regarding Hodgkin's lymphoma as well as rarer entities, such as T cell lymphomas.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
Inserm
Collections :
  • Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:07:02Z
Université de Lille

Mentions légales
Université de Lille © 2017